Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
P. Verschueren*, D. de Cock, L. Corluy, R. Joos, C. Langenaken, V. Taelman, F. Raeman, I. Ravelingien, K. Vandevyvere, J. Lenaerts, E. Geens, P. Geusens, J. Vanhoof, A. Durnez, J. Remans, B. vander Cruyssen, E. van Essche, A. Sileghem, G. de Brabanter, J. JolyK. van der Elst, S. Meyfroidt, R. Westhovens, the CareRA study group
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial'. Together they form a unique fingerprint.